Biogen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. 

CEO
Christopher A. Viehbacher
CEOChristopher A. Viehbacher
Employees
7,605
Employees7,605
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1978
Founded1978
Employees
7,605
Employees7,605

BIIB Key Statistics

Market cap
21.32B
Market cap21.32B
Price-Earnings ratio
14.31
Price-Earnings ratio14.31
Dividend yield
Dividend yield
Average volume
2.03M
Average volume2.03M
High today
$150.20
High today$150.20
Low today
$144.74
Low today$144.74
Open price
$149.84
Open price$149.84
Volume
978.40K
Volume978.40K
52 Week high
$194.13
52 Week high$194.13
52 Week low
$110.04
52 Week low$110.04

BIIB News

Barchart 11h
What to Expect From Biogen’s Q3 2025 Earnings Report

Valued at a market cap of $22.1 billion, Biogen Inc. (BIIB) is a top biotechnology company. Headquartered in Cambridge, Massachusetts, it specializes in the dis...

Nasdaq 16h
Biogen And Stoke Therapeutics Present Promising Long-Term Data For Zorevunersen In Dravet Syndrome

(RTTNews) - Biogen Inc. (BIIB) and Stoke Therapeutics Inc. (STOK) unveiled new long-term follow-up data from ongoing open-label extension (OLE) studies of zorev...

Biogen And Stoke Therapeutics Present Promising Long-Term Data For Zorevunersen In Dravet Syndrome
TipRanks 23h
Biogen, Stoke Therapeutics present follow-up analyses from zorevunersen studies

Biogen (BIIB) and Stoke Therapeutics (STOK) announced the presentation of longer-term follow-up analyses from the ongoing open-label extension studies of zorevu...

Analyst ratings

51%

of 37 ratings
Buy
48.6%
Hold
51.4%
Sell
0%

More BIIB News

Simply Wall St 23h
Where Does Biogen Stand After Recent 7% Rally Amid Alzheimer’s Drug Developments?

If you own Biogen stock, or are thinking about buying in, you might be wondering what to make of all the recent movement in its share price. Over the last month...

Where Does Biogen Stand After Recent 7% Rally Amid Alzheimer’s Drug Developments?
Nasdaq 4d
Eisai And Biogen : LEQEMBI IQLIK Injection Now Available In U.S. For Early Alzheimer's Treatment

(RTTNews) - Eisai Co., Ltd. (ESALY.PK, ESALF.PK, 4523.T) and Biogen Inc. (BIIB) announced the U.S. availability of LEQEMBI IQLIK (lecanemab-irmb) as a subcutane...

Eisai And Biogen : LEQEMBI IQLIK Injection Now Available In U.S. For Early Alzheimer's Treatment
TipRanks 4d
Eisai, Biogen announces Leqembi Iqlik availability in the U.S.

Eisai (ESAIY) and Biogen (BIIB) announced that lecanemab-irmb subcutaneous injection, or Leqembi Iqlik, is now available in the U.S. as a maintenance dosing reg...

Simply Wall St 5d
A Look at Biogen Valuation Following Australian LEQEMBI Approval and Fresh Analyst Optimism

Biogen (BIIB) just saw Australia’s Therapeutic Goods Administration approve LEQEMBI for early Alzheimer’s in adults. This marks a fresh milestone that expands a...

A Look at Biogen Valuation Following Australian LEQEMBI Approval and Fresh Analyst Optimism

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.